CIM240719C15000
- 0.03
- -0.14-82.35%
Chimera Investment Corp Newsroom
Chimera Investment Analyst Ratings
Keefe, Bruyette & Woods Maintains Market Perform on Chimera Investment, Maintains $15 Price Target
UBS Initiates Coverage On Chimera Investment With Neutral Rating, Announces Price Target of $5.5
Chimera Investment Analyst Ratings
Credit Suisse Maintains Neutral on Chimera Investment, Lowers Price Target to $5.5
What 5 Analyst Ratings Have To Say About Chimera Investment
RBC Capital Maintains Outperform on Chimera Investment, Lowers Price Target to $6
RBC Cuts Price Target on Chimera Investment to $6 From $7, Maintains Outperform Rating
Keefe, Bruyette & Woods Maintains Market Perform on Chimera Investment, Lowers Price Target to $5.5
Keefe, Bruyette & Woods Adjusts Price Target on Chimera Investment to $6.25 From $7, Maintains Market Perform Rating
Keefe, Bruyette & Woods Maintains Market Perform on Chimera Investment, Lowers Price Target to $6.25
Credit Suisse Sticks to Their Hold Rating for Chimera Investment (CIM)
Credit Suisse Reiterates Neutral on Chimera Investment, Maintains $6.5 Price Target
RBC Capital Reiterates Outperform on Chimera Investment, Maintains $7 Price Target
RBC Cuts Price Target on Chimera Investment to $7 From $11, Noting Unexpected Dividend Cut, Maintains Outperform Rating
Chimera Investment Analyst Ratings
RBC Capital Maintains Outperform on Chimera Investment, Lowers Price Target to $7
Barclays Adjusts Price Target on Chimera Investment to $9 From $11, Reiterates Underweight Rating
Chimera Investment Price Target Cut to $9.00/Share From $11.00 by Barclays
Chimera Investment Is Maintained at Underweight by Barclays